- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Innova Captab Limited has announced a board meeting on 31st July 2025 to consider the financial results for the quarter and half-year. The company reported a strong FY 2025 performance with consolidated revenue growing 15.0% to ₹ 1244 Cr, driven by all business segments. The CDMO business remained the largest contributor with revenues of ₹ 660 Cr (53% of total), followed by Domestic Branded Generics at ₹ 231 Cr and International Branded Generics at ₹ 156 Cr. The acquisition of Sharon Bio-Medicine enhanced product range, international reach, and API capabilities, contributing ₹ 197 Cr revenue. EBITDA rose 18.7% to ₹ 198 Cr with a margin of 15.9%, while PAT increased 35.9% to ₹ 128 Cr. The company successfully commercialized its greenfield manufacturing facility in Kathua, Jammu, with a capital investment of over ₹ 480 Cr, adding capacity in Cephalosporin, Penem, Penicillin, injectables, and respules. The facility benefits from central government incentives that are expected to boost profitability and return on investment. Innova’s financial discipline is reflected in a gearing ratio of 0.40 and a ROE of 13.4%. The company continues to invest in R&D with facilities in Baddi and Panchkula, focusing on complex generics and innovation. Corporate governance practices remain strong with an experienced board and various board committees overseeing operations. No dividend is proposed to conserve resources for growth and expansion. The company has maintained compliance with applicable laws, has no material litigation impacting operations, and continues committing to sustainability through initiatives in energy efficiency, waste and water management, and social responsibility.